Antibodies News and Research

RSS

Study reveals maternal and neonatal benefits of Pfizer COVID-19 mRNA vaccine

A new commentary, published as an ‘In-Press Preview’ in the Journal of Clinical Investigation, addresses the salient issue of vaccination against the coronavirus disease (COVID-19) in pregnancy and potential antibody transfer to the fetus – and provides the evidence in support of messenger RNA (mRNA) vaccine safety and efficacy for both maternal and child health.

13 Jun 2021

Study shows poor antibody response in naive elderly of nursing homes after mRNA vaccination

A new study describes inadequate antibody responses to the Pfizer/BioNTech vaccine against coronavirus disease 2019 (COVID-19) in elderly residents of a care home with no prior history of infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), compared to those with such a history. This adds to the current understanding of vaccine efficacy against infection.

13 Jun 2021

AI identifies gene signatures to reveal patients’ immune responses to viral infection

Researchers at University of California San Diego School of Medicine used an artificial intelligence (AI) algorithm to sift through terabytes of gene expression data -- which genes are "on" or "off" during infection -- to look for shared patterns in patients with past pandemic viral infections, including SARS, MERS and swine flu.

11 Jun 2021

High single-dose efficacy of Pfizer vaccine against SARS-CoV-2 in older adults

In British Columbia (BC), Canada, vaccination against coronavirus disease 2019 (COVID-19) began with the Pfizer/Moderna mRNA (messenger ribonucleic acid) vaccines began with nursing home residents and frontline healthcare workers. These are known to have a high protective efficacy of 92-93% after a single dose, but this data comes from younger and healthy adults, for the most part.

11 Jun 2021

New Astra-Zeneca B.1.351 vaccine AZD2816 strongly immunogenic against multiple SARS-CoV-2 variants of concern

A new study, released on the bioRxiv* preprint server, supports the efficacy of the wildtype ChAdOx1 nCoV-19 (AZD1222) vaccine against B.1.351, B.1.617.1 and B.1.617.2, while showing that a booster dose of vaccine based on the B.1.351 spike induces further increase in antibody titers.

11 Jun 2021

Scientists detect delayed and reduced antibody responses after BioNTech/Pfizer COVID-19 vaccination in older adults

Researchers at the U.S. Centers for Disease Control and Prevention (CDC) detected delayed and reduced antibody and T cell responses after immunization with BNT162b2 or the Pfizer-BioNTech COVID-19 vaccine in older adults compared with healthcare workers in Germany.

11 Jun 2021

SARS-CoV-2 infection detected in a poodle living with a COVID-19 positive family

Researchers in Italy identified a case of reverse zoonosis wherein animals contract the virus from humans. The team detected SARS-CoV-2 in a healthy poodle living with four family members who had COVID-19.

11 Jun 2021

Bio-inspired robot reveals motion pattern of ray sperms

It is generally agreed that sperms "swim" by beating or rotating their soft tails. However, a research team led by scientists from City University of Hong Kong (CityU) has discovered that ray sperms move by rotating both the tail and the head.

11 Jun 2021

Nanobodies from nanomice and llamas show potent neutralizing activity against SARS-CoV-2 variants

While several COVID-19 vaccines have been approved to date, the constant evolution of the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) receptor-binding domain (RBD) has challenged the efficacy of these vaccines.

11 Jun 2021

In vivo protection from emerging SARS-CoV-2 variants by protein nanoparticle vaccine

Researchers in the United States have developed a new coronavirus disease 2019 (COVID-19) vaccine that induced potent neutralizing antibodies against variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in animal models.

10 Jun 2021

Shark vNAR antibodies inhibit SARS-CoV-2 variants in vitro

Researchers in the UK and Austria have identified a novel class of antibodies that is highly effective at neutralizing the original strain of severe acute respiratory syndrome (SARS-CoV-2) and maintaining blocking activity against certain viral variants that have emerged.

10 Jun 2021

Discovery suggests new pathways for safeguarding the immune system’s ability to fight cancer

In order for cancer to grow and spread, it has to evade detection by our immune cells, particularly specialized "killer" T cells.

10 Jun 2021

ACTG launches phase 1 HIV cure study evaluating two promising therapies

The AIDS Clinical Trials Group, the largest global HIV research network, today announced the launch of A5386, a phase 1 HIV cure study evaluating two promising therapies.

10 Jun 2021

The longevity of SARS-CoV-2 antibodies and their cross-neutralization against variants of concern

In a new study by researchers in the UK, the activity of neutralizing antibodies collected from the sera of individuals that contracted COVID-19 during the first wave of the pandemic is tested against variants of concern the B.1.1.7 (or UK) variant and the B.1.351 (or South African) variant, demonstrating somewhat reduced potency of neutralization towards these strains.

10 Jun 2021

Bovine-derived polyclonal antibodies exhibit high efficacy in neutralizing SARS-CoV-2 variants

A team of scientists in Estonia has recently evaluated the therapeutic/prophylactic efficacy of anti-SARS-CoV-2 polyclonal antibodies derived from the colostrum of immunized cows.

10 Jun 2021

Is B.1.617.2 more transmissible than earlier SARS-CoV-2 variants?

A new study, released as a preprint on the medRxiv* server, reports that the B.1.617.2 variant is possibly more transmissible than earlier variants, based on the discovery that the serial intervals were not prolonged with this strain.

10 Jun 2021

Could the COVID-19 vaccination rollout protect against future coronavirus outbreaks?

A new study suggests that the rollout of vaccines against the COVID-19 pandemic may be significant not only in preventing infections by SARS-CoV-2 but other endemic and pandemic-potential coronaviruses (CoVs) as well.

10 Jun 2021

Study reports on the immunogenicity of single-shot COVID-19 vaccine against SARS-CoV-2 variants

In the three months since Johnson & Johnson's COVID-19 vaccine received emergency use authorization from the U.S. Food and Drug Administration, more than 10 million Americans have received the vaccine, according to the Centers for Disease Control and Prevention.

9 Jun 2021

What are the challenges of SARS-CoV-2 serosurveillance in COVID-19 vaccine recipients?

An opinion paper by researchers from the US and Italy recently discussed various aspects of monitoring anti-SARS-CoV-2 antibodies before and after receiving COVID-19 vaccination to highlight the pros and cons of this monitoring strategy. This paper is published in the open-access journal Diagnostics.

9 Jun 2021

Mix and match COVID-19 vaccines safe and effective: German study

A new preprint study posted to the medRxiv* server shows an AstraZeneca’s ChAdOx1-nCov-19 and Pfizer/BioNTech BNT162b2 COVID-19 vaccine combination is immunologically superior to two AstraZeneca ChAdOx1-nCov-19 doses.

9 Jun 2021

Antibodies News and Research

Study reveals maternal and neonatal benefits of Pfizer COVID-19 mRNA vaccine

Study shows poor antibody response in naive elderly of nursing homes after mRNA vaccination

AI identifies gene signatures to reveal patients’ immune responses to viral infection

High single-dose efficacy of Pfizer vaccine against SARS-CoV-2 in older adults

New Astra-Zeneca B.1.351 vaccine AZD2816 strongly immunogenic against multiple SARS-CoV-2 variants of concern

Scientists detect delayed and reduced antibody responses after BioNTech/Pfizer COVID-19 vaccination in older adults

SARS-CoV-2 infection detected in a poodle living with a COVID-19 positive family

Bio-inspired robot reveals motion pattern of ray sperms

Nanobodies from nanomice and llamas show potent neutralizing activity against SARS-CoV-2 variants

In vivo protection from emerging SARS-CoV-2 variants by protein nanoparticle vaccine

Shark vNAR antibodies inhibit SARS-CoV-2 variants in vitro

Discovery suggests new pathways for safeguarding the immune system’s ability to fight cancer

ACTG launches phase 1 HIV cure study evaluating two promising therapies

The longevity of SARS-CoV-2 antibodies and their cross-neutralization against variants of concern

Bovine-derived polyclonal antibodies exhibit high efficacy in neutralizing SARS-CoV-2 variants

Is B.1.617.2 more transmissible than earlier SARS-CoV-2 variants?

Could the COVID-19 vaccination rollout protect against future coronavirus outbreaks?

Study reports on the immunogenicity of single-shot COVID-19 vaccine against SARS-CoV-2 variants

What are the challenges of SARS-CoV-2 serosurveillance in COVID-19 vaccine recipients?

Mix and match COVID-19 vaccines safe and effective: German study

A new way of characterising biomolecules eBook

Leveraging the power of automation to boost research

Automating research - solutions and best practices

How can microdialysis benefit drug development

Latest Life Science News